Zhuhai-based pharmaceutical group making generics, diagnostic reagents and biologic/vaccine products.
Zhuhai-based pharmaceutical group making generics, diagnostic reagents and biologic/vaccine products.
Sells medicines and diagnostic kits to Chinese hospitals and labs, where government drug-purchasing rules press prices on older generics and test kits sell on lab volume. Joincare Pharmaceutical, a listed Chinese drug group, is the controlling shareholder. The same company also trades in Hong Kong as 1513.HK.
Moat: narrow (scale, regulatory licence). Broad, diversified drug and diagnostics portfolio built over decades.
Headquarters: Zhuhai, China · Employees: 8,878
Size Livzon Pharmaceutical (000513.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $3.76B, the 641st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥31.99 on 18 Nov 2026.
Performance Over six months the shares gained 3.6%, against +1.6% for the median peer and -20.0% for the China market (cap-weighted) — 9th highest of 19 in its peer set.
Growth Revenue fell 13.7% over the last twelve months (peer median +10.3%); the operating margin is 19.2% (peer median 15.7%).
Valuation It trades at 16.9× forward earnings against a peer median of 21.0× (5th cheapest of 13).
Price implies For today's price to make sense, revenue must grow about -10% a year for seven years (Req g). Recent delivered growth is +3%, so the hurdle is -12 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 10.1 points above its cost of capital (5.0% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥10.2B | CN¥11.9B | CN¥11.7B | CN¥12.3B | CN¥12.5B |
| Revenue growth | — | +2% | -5% | -2% | — |
| Gross profit | CN¥6.62B | CN¥7.63B | CN¥7.45B | CN¥7.40B | CN¥7.75B |
| EBITDA | n/a | CN¥3.18B | CN¥3.18B | CN¥2.79B | CN¥2.60B |
| Net income | CN¥1.56B | CN¥2.02B | CN¥2.06B | CN¥1.95B | CN¥1.91B |
| Free cash flow | CN¥2.77B | CN¥2.60B | CN¥2.42B | CN¥2.57B | CN¥1.96B |
| Capital expenditure | CN¥412M | CN¥574M | CN¥570M | CN¥820M | CN¥940M |
| Total debt | CN¥4.20B | CN¥3.85B | CN¥4.95B | CN¥5.04B | CN¥4.63B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Livzon Pharmaceutical 000513.SZ | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% |
| Shenzhen Salubris Pharmaceuticals 002294.SZ | $4.31B | -24% | +14% | 11% | 35.4× | 12.4% |
| Humanwell Healthcare (Group) 600079.SS | $4.87B | +11% | +2% | 15% | 13.8× | -8.8% |
| Huadong Medicine 000963.SZ | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | $7.57B | -14% | +8% | 6% | 14.8× | 2.9% |
| Cspc Pharma 1093.HK | $12.0B | +10% | +25% | 28% | 9.1× | -10.7% |
| Hualan Biological Engineering 002007.SZ | $3.20B | -17% | -11% | 17% | 26.7× | 15.8% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 000513.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +17.4% | -0.2% | 3rd highest of 21 |
| 6-month return | +3.6% | +1.6% | 9th highest of 19 |
| Distance from 52-week high | -15.5% | -29.5% | 5th highest of 21 |
| Revenue growth (TTM) | -13.7% | +10.3% | 2nd lowest of 18 |
| Operating margin | 19.2% | 15.7% | 7th highest of 17 |
| Forward P/E | 16.9× | 21.0× | 5th cheapest of 13 |
| Growth the price implies (Req g, 7 yrs) | -9.6% | 5.5% | least demanding of 13 |
| Growth delivered (Del g) | +2.7% | +7.7% | 3rd lowest of 13 |
| Hurdle (Req g minus delivered) | -12.3 pp | -7.0 pp | 6th least demanding of 13 |
| ROIC minus cost of capital | +10.1 pp | +4.3 pp | 5th highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Livzon Pharmaceutical 000513.SZ | China | $3.76B | +4% | -14% | 19% | 16.9× | -9.6% | +2.7% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $3.75B | -10% | -13% | 20% | 28.5× | 16.2% | -5.8% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.75B | +12% | +14% | 20% | 21.9× | 1.2% | +12.1% |
| Tarsus Pharmaceuticals TARS | United States | $3.74B | +17% | +86% | -10% | n/a | 34.7% | +159.5% |
| Xenon Pharmaceuticals XENE | United States | $3.71B | -31% | -100% | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $3.81B | -38% | +227% | 74% | 39.9× | 0.9% | +45.1% |
| SELLAS Life Sciences SLS | United States | $3.66B | +100% | n/a | n/a | n/a | n/a | n/a |
| Organon & OGN | United States | $3.66B | +3% | -3% | 20% | 4.0× | -4.1% | -1.0% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.61B | 0% | +10% | 12% | 20.1× | 6.4% | +5.9% |
| Novast Laboratories 301569.SZ | China | $3.92B | n/a | +3% | 27% | n/a | 57.4% | +3.1% |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.60B | -7% | +8% | 4% | 5.8× | -4.9% | +7.8% |
| HanmiPharm 128940.KS | South Korea | $3.95B | -2% | +14% | 16% | 15.0× | 4.7% | +7.5% |
| Definium Therapeutics DFTX | United States | $3.99B | +40% | n/a | n/a | n/a | n/a | n/a |
| Wockhardt WOCKPHARMA.NS | India | $3.52B | +25% | +26% | 13% | n/a | 58.0% | +4.2% |
| Parabilis Medicines PBLS | United States | $3.52B | n/a | n/a | n/a | n/a | n/a | n/a |
| Siegfried SFZN.SW | Switzerland | $3.51B | -17% | +4% | 16% | 16.8× | n/a | n/a |
| Acutaas Chemicals ACUTAAS.NS | India | $3.50B | +38% | +45% | 36% | 63.6× | n/a | n/a |
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $3.49B | -38% | +36% | -14% | n/a | n/a | n/a |
| Arcutis Biotherapeutics ARQT | United States | $3.49B | +35% | +60% | 7% | 41.0× | 49.2% | +367.3% |
| Jiangsu Nhwa Pharmaceutical 002262.SZ | China | $3.48B | +8% | +3% | 19% | 19.6× | -2.1% | +12.0% |
| Yuhan 000100.KS | South Korea | $4.11B | -10% | +8% | 6% | 40.4× | n/a | n/a |